About ZYUS Life Sciences
ZYUS Life Sciences is a company based in Saskatoon (Canada) founded in 2018 by Brent Zettl. ZYUS Life Sciences has raised $19.5 million across 10 funding rounds. ZYUS Life Sciences has completed 1 acquisition, including Revon Systems. ZYUS Life Sciences operates in a competitive market with competitors including Sanity Group, Terraflos, Avicanna, Little Green Pharma and IMCannabis, among others.
- Headquarter Saskatoon, Canada
- Founders Brent Zettl
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zyus Life Sciences Corporation
-
Annual Revenue
$334.3 K (USD)37.04as on Dec 31, 2024
-
Net Profit
-$23.49 M (USD)20.63as on Dec 31, 2024
-
EBITDA
-$8.58 M (USD)22.48as on Dec 31, 2024
-
Total Equity Funding
$19.5 M (USD)
in 10 rounds
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ZYUS Life Sciences
ZYUS Life Sciences is a publicly listed company on the TSXV with ticker symbol ZYUS in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of ZYUS Life Sciences
Unlock access to complete
Funding Insights of ZYUS Life Sciences
ZYUS Life Sciences has successfully raised a total of $19.5M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by ZYUS Life Sciences
ZYUS Life Sciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Revon Systems.
Investment portfolio details for ZYUS Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Digital therapeutic solutions for chronic care management are offered.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for ZYUS Life Sciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ZYUS Life Sciences
Detailed financials for ZYUS Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zyus Life Sciences Comparisons
Peer comparison for ZYUS Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ZYUS Life Sciences
ZYUS Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sanity Group, Terraflos, Avicanna, Little Green Pharma and IMCannabis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cannabinoid-based pharmaceuticals and well-being products
|
|
| Locked | Locked | Locked |
Medical cannabis products are provided based on GMP processes.
|
|
| Locked | Locked | Locked |
Plant-derived cannabinoid products are developed for medical and consumer uses.
|
|
| Locked | Locked | Locked |
Manufacturer of medicinal cannabis for therapeutic use
|
|
| Locked | Locked | Locked |
Developer of medical cannabis products
|
Detailed competitors of ZYUS Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zyus Life Sciences
Complete news archive for ZYUS Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZYUS Life Sciences
ZYUS Life Sciences was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ZYUS Life Sciences is headquartered in Saskatoon, Canada. It is registered at Saskatoon, Saskatchewan, Canada.
Brent Zettl is the current CEO of ZYUS Life Sciences. They have also founded this company.
ZYUS Life Sciences is a funded company, having raised a total of $19.5M across 10 funding rounds to date.
Annual revenue of ZYUS Life Sciences is $334.3K as on Dec 31, 2024.
ZYUS Life Sciences was founded in 2018 in Saskatoon, Canada, within the biotechnology sector. Cannabis-derived therapeutics are developed for various medical indications, with emphasis on cannabinoid-based products and protein-based formulations. Targeted relief is provided to patients through these innovations. The lead candidate, Trichomylin, is designed to address chronic pain. Operations center on research and formulation development in this specialized field.
ZYUS Life Sciences's top competitors include Avicanna, Neocannbio and IMCannabis.
Yes, ZYUS Life Sciences is publicly traded on TSXV under the ticker symbol ZYUS.
ZYUS Life Sciences has made 1 acquisition, including Revon Systems.
The ticker symbol of ZYUS Life Sciences is ZYUS on TSXV.